SARS-CoV-2 - Colchicine - Therapeutic Candidates

SARS-CoV-2 - Colchicine - Therapeutic Candidates


Colchicine is an anti-inflammatory drug used in rheumatology and particularly for the treatment of gouty arthritis or gout. Colchicine is also used in the treatment of other pathologies such as chronic atrophic polychondritis or acute pericarditis after failure of aspirin. 
Studies have shown that SARS-CoVs activate NLRP3 inflammasomes, intracytoplasmic particles that stimulate the release of pro-inflammatory cytokines. In particular, colchicine is believed to inhibit the assembly of the NLRP3 inflammasome and thus the release of cytokines, in particular interleukin-1 beta and interleukin-6. Colchicine is believed to inhibit certain functions of the inflammasome, a component of the immune system that plays a role in triggering cytokine shock and the associated inflammatory cascade. Targeting the inflammatory response with colchicine may therefore reduce complications related to Covid-19 in adults at risk or with signs of inflammatory storm. Three studies are currently underway to investigate the effects of colchicine on Covid-19, the largest, called COLCORONA, involves 6000 patients in Canada.

Cat#
Description
Size
Price Excl. VAT
abx082250-1000mg
 1000mg 
015712-10mg
 10mg 
409639-10mg
 10mg 
409639-50mg
 50mg 
A10238-1000
 1000mg 
D230880-100mg
 100mg 
A10238-2000
 2000mg 
D2741-06-01-1mg
 1mg 
D2741-06-10mg
 10mg 
290128-100mg
 100mg 
290128-50mg
 50mg 
D231730-10mg
 10mg 
D2741-54-10mg
 10mg 
D230885-100mg
 100mg 
D231730-25mg
 25mg 
D230885-250mg
 250mg 
D231730-5mg
 5mg 
D230885-25mg
 25mg 
D230885-500mg
 500mg 
D230885-50mg
 50mg 
045335-25mg
 25mg 
T0320-100mg
 100mg 
T0320-1ml
 1 ml 10 mm in dmso 
A549775-2.5mg
 2.5mg 
Number of results per page : 10 50 250